BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32054837)

  • 21. The Epstein-Barr Virus Episome Maneuvers between Nuclear Chromatin Compartments during Reactivation.
    Moquin SA; Thomas S; Whalen S; Warburton A; Fernandez SG; McBride AA; Pollard KS; Miranda JL
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The AT-hook DNA binding ability of the Epstein Barr virus EBNA1 protein is necessary for the maintenance of viral genomes in latently infected cells.
    Chakravorty A; Sugden B
    Virology; 2015 Oct; 484():251-258. PubMed ID: 26122471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
    Schaefer BC; Strominger JL; Speck SH
    Mol Cell Biol; 1997 Jan; 17(1):364-77. PubMed ID: 8972217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EBNA1 regulates cellular gene expression by binding cellular promoters.
    Canaan A; Haviv I; Urban AE; Schulz VP; Hartman S; Zhang Z; Palejev D; Deisseroth AB; Lacy J; Snyder M; Gerstein M; Weissman SM
    Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22421-6. PubMed ID: 20080792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
    Kennedy G; Komano J; Sugden B
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
    Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
    PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type I latency Burkitt's lymphoma cells.
    Lin Z; Xu G; Deng N; Taylor C; Zhu D; Flemington EK
    J Virol; 2010 Dec; 84(24):13053-8. PubMed ID: 20943983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
    Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
    Hochberg D; Middeldorp JM; Catalina M; Sullivan JL; Luzuriaga K; Thorley-Lawson DA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):239-44. PubMed ID: 14688409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance.
    Shire K; Ceccarelli DF; Avolio-Hunter TM; Frappier L
    J Virol; 1999 Apr; 73(4):2587-95. PubMed ID: 10074103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1.
    Wu H; Ceccarelli DF; Frappier L
    EMBO Rep; 2000 Aug; 1(2):140-4. PubMed ID: 11265753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.
    Gruhne B; Sompallae R; Masucci MG
    Oncogene; 2009 Nov; 28(45):3997-4008. PubMed ID: 19718051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines.
    Touitou R; Arbach H; Cochet C; Feuillard J; Martin A; Raphaël M; Joab I
    J Gen Virol; 2003 Apr; 84(Pt 4):949-957. PubMed ID: 12655096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
    Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
    Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
    Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
    Woellmer A; Arteaga-Salas JM; Hammerschmidt W
    PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
    Takacs M; Segesdi J; Banati F; Koroknai A; Wolf H; Niller HH; Minarovits J
    Mediterr J Hematol Infect Dis; 2009 Nov; 1(2):e2009012. PubMed ID: 21416002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.
    Pimienta G; Fok V; Haslip M; Nagy M; Takyar S; Steitz JA
    PLoS One; 2015; 10(6):e0124638. PubMed ID: 26121143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment.
    Norseen J; Johnson FB; Lieberman PM
    J Virol; 2009 Oct; 83(20):10336-46. PubMed ID: 19656898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.